Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYME Form 4 May 06, 2016	E THERAPEU	UTICS INC									
FORM	Λ									PPROVAL	
	SECURITIES AND EXCHANGE C Washington, D.C. 20549					COMMISSION	OMB Number:	3235-0287			
Check this box if no longer							Expires:	January 31,			
subject to Section 16 Form 4 or	5. STATEMENT OF CHANGES IN BENEFICIAL O SECURITIES							NERSHIP OF	Estimated a burden hou	rs per	
Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed p s Section 1	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						response n	0.5		
(Print or Type R	esponses)										
Daly James M Sy: Hz			Symbol HALOZ	YME TH	l Ticker or T IERAPEU			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			INC [HA	-							
(Mor				Date of Earliest Transaction Month/Day/Year) 5/04/2016				XDirector Officer (give below)		• Owner er (specify	
	(Street)		4. If Amendment, Date Original 6. I			6. Individual or Joint/Group Filing(Check					
				th/Day/Year	-			Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	T .11			•	• • •	·			
							-	uired, Disposed of		-	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ear) Execution any	med on Date, if Day/Year)	3. Transacti Code (Instr. 8) Code V	on(A) or Dis (D) (Instr. 3, 4)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	05/04/2016			А	20,202 (1)	А	\$0	20,202	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Tit Amou Unde: Secur (Instr	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Reporting Owners

5

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Daly James M C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121	Х							
Signatures								
James R. Oehler as attorney-in-fact for James Daly	s M. 05/06/2016							
**Signature of Reporting Person		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) (1) May 4, 2017 and (ii) the date of the Issuer's next annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.